Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 agonists like Ozempic are primarily used to treat type 2 diabetes. Its popularity has even influenced wholesale retailer ...

The new class of drugs has changed the game when it comes to weight loss. What are the key dietary considerations you need to ...

Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

Stopping GLP-1 weight loss drugs like Ozempic and Wegovy often leads to rapid weight regain and returning health risks.

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

The researchers found that patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS versus the non-GLP-1 RA group at one-year (risk ratio [RR], 0.64) and five-year follow-up ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

GLP-1 RA use was associated with significantly lower epilepsy risk, with protective associations seen at 1, 3, and 5 years. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Glucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have gained popularity globally, not just for managing type 2 diabetes but also due to ...